|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Together, these data implicate increased AKT activity in prostate tumor progression and androgen independence and suggest that diminished p27(Kip1) expression, which has been repeatedly associated with prostate cancer progression, may be a consequence of increased AKT activity.
|
10827191 |
2000 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
|
11461904 |
2001 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
These studies identify a new mechanism for androgen-mediated prostate cancer cell survival that appears to be independent of the activity of the receptor on androgen response element-mediated transcription and establish FKHR and related FOXO forkhead proteins as important nuclear targets for both AKT-dependent and -independent survival signals in prostate cancer cells.
|
12482965 |
2003 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
In the MNU model, the progressive evolution of dominant tumor cell populations showing an increase in p-AKT in parallel with a decline in AR staining suggests that activation of AKT signaling may be one of several mechanisms contributing to androgen insensitivity during prostate cancer progression.
|
15682402 |
2005 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Integrin-linked kinase (ILK) has been shown to regulate PKB/Akt activity with the loss of PTEN in prostate cancer.
|
15782140 |
2005 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we showed that (a) CXCL12/CXCR4 axis is expressed in PC bone metastasis; (b) exogenous CXCL12 induced MMP-9 expression by PC cells; (c) bone stromal cells and bone tissue conditioned media induced the migration of PC cells in a CXCR4-dependent manner; (d) pharmacological inhibition of PI3 kinase and MAP kinase pathways abrogated CXCL12-induced MMP-9 expression and invasion of PC cells; (e) exogenous CXCL12 induced Akt1 phosphorylation is indispensable for proMMP-9 secretion, migration, and invasion of PC cells; (f) CXCR4 was localized to lipid rafts in PC cells and initiated Akt phosphorylation.
|
16114056 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that more efficient therapeutics for advanced prostate cancer may need to target simultaneously AR signaling and AKT or the growth factor receptor tyrosine kinases that activate AKT.
|
16682621 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Luteolin inhibited insulin-like growth factor 1 (IGF-1) induced activation of IGF-1R and AKT in prostate cancer PC-3 and DU145 cells.
|
17065200 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, patients who had prostate cancers with concomitant loss of NEP and expression of phosphorylated Akt had an increased, independent risk of prostate-specific antigen (PSA) recurrence (P = .03).
|
17083125 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our data suggest that increased Rac protein expression in prostate cancer relative to the corresponding benign secretory epithelium is an independent predictor of decreased DFS and appears to result mainly from increased expression of the Rac3 isoform.
|
17639041 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, molecular evidence revealed that PC-1 expression stimulated Akt/protein kinase B signaling pathway, which has been implicated to play important roles in promoting androgen refractory progression in prostate cancer.
|
17875733 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Down-regulation of the PIK3/PKB pathway by repression of involved effector and regulator genes at all stages of the molecular pathway could represent a marker for the formation of highly de-differentiated prostate cancers from low-grade tumour foci.
|
18336616 |
2008 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer.
|
18497063 |
2008 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation.
|
18611860 |
2008 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
|
18627304 |
2008 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Collectively, these results suggest that the molecular consequences of NKX3.1 loss depend on the epithelial proliferative stage at which its expression is lost, and that alterations in the PTEN-AKT-NKX3.1 axis are important for prostate cancer initiation.
|
19597465 |
2009 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The E17K substitution in AKT1 is rare in prostate cancer.
|
20407443 |
2010 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, these data in a mouse prostate cell system uncover for the first time a novel and complex relationship between PTEN loss-mediated PI3K/AKT activation and posttranslational regulation of MT1-MMP, which may play a role in PC progression.
|
20620173 |
2010 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among many functions, PTEN negatively regulates the cytoplasmic phosphatidylinositol-3-kinase/AKT anti-apoptotic pathway; and nuclear PTEN affects the cell cycle by also negatively regulating the MAPK pathway via cyclin D. Decreased PTEN expression is correlated with prostate cancer progression.
|
20729295 |
2010 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we demonstrate that Tan IIA significantly decreased the viable cell number of LNCaP (phosphate and tensin homolog (PTEN) mutant, high AKT, wild type p53) prostate cancer cells more sensitively than against the PC-3 (PTEN null, high AKT, p53 null) prostate cancer cells.
|
21048307 |
2010 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Expression of GRP78 and key Hsp70-hsp90 client proteins (HER2, HER3, AR and AKT) were studied in an incidence tissue microarray (TMA) of prostate cancer.
|
21125667 |
2011 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our previous data suggest that the PTEN/PI3K/AKT pathway is critical for the in vitro maintenance of CD133(+)/CD44(+) prostate cancer progenitors and, consequently, that targeting PI3K signaling may be beneficial in treatment of prostate cancer.
|
21138868 |
2010 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diallyl trisulfide-induced prostate cancer cell death is associated with Akt/PKB dephosphorylation mediated by P-p66shc.
|
22020565 |
2012 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, these data suggest that a strong selective growth advantage for loss of PTEN and upregulation of PI3K/AKT, combined with the close proximity of PTEN to a large unstable segment of repeated DNA comprising SD17 and SD18, can lead to recurrent microdeletions of the PTEN gene in prostate cancer.
|
22045666 |
2012 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased activation of the AKT and NFkB pathways have been identified as critical steps in prostate cancer initiation and progression.
|
22389719 |
2012 |